Cite
189PDTumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04).
MLA
Rossum, A. G. J.van, et al. “189PDTumor Infiltrating Lymphocytes Predict Benefit from TAC but Not from DdAC in Triple Negative Breast Cancer in the Randomized MATADOR Trial (BOOG 2004-04).” Annals of Oncology, vol. 29, Oct. 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdy270.186.
APA
Rossum, A. G. J. van, Hoogstraat, M., Opdam, M., Horlings, H., Wessels, L., Kerkhoven, R. M., Stok, A. E. van L.-, Oosterkamp, H. M., Kok, M., & Linn, S. C. (2018). 189PDTumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04). Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy270.186
Chicago
Rossum, A G J van, M Hoogstraat, M Opdam, H Horlings, L Wessels, R M Kerkhoven, A E van Leeuwen - Stok, H M Oosterkamp, M Kok, and S C Linn. 2018. “189PDTumor Infiltrating Lymphocytes Predict Benefit from TAC but Not from DdAC in Triple Negative Breast Cancer in the Randomized MATADOR Trial (BOOG 2004-04).” Annals of Oncology 29 (October): N.PAG. doi:10.1093/annonc/mdy270.186.